Tenecteplase after clot removal for no-reflow stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether giving tenecteplase directly into the brain artery after a thrombectomy can improve outcomes when blood flow doesn’t fully return (“no-reflow”) in an emergency stroke. It may help some people by reducing ongoing clot-related blockage after the main clot is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older with an ischemic stroke caused by a large-vessel clot (in the internal carotid, or MCA M1 or M2).
- You can start the study treatment within 24 hours of symptom onset and the treating team plans thrombectomy using standard criteria.
- Your brain scan results fit the trial: no bleeding on CT/MRI, and ASPECTS score is at least 3 (not 0–2).
- If symptoms started 6–24 hours ago, your scan shows an ischemic core volume under 100 mL.
- You had a CT/MRI perfusion/CT check close to the study timing (within the required imaging window) and you meet pre-stroke independence needs (mRS 0–2).
- You are able to consent based on local legal requirements and are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving IV TNK (tenecteplase) plus standard stroke care can improve outcomes in some people who have a new stroke but cannot get alteplase (another clot-busting drug) and do not have a large blocked artery that can be treated with a procedure. It’s meant for strokes with “mismatch” findings on scans that suggest salvageable brain tissue.
This trial tests if giving a clot-busting drug (tenecteplase) directly into the brain artery after a successful clot-removal procedure can improve outcomes for people with a major stroke. It is for patients who had a large vessel blockage and received endovascular thrombectomy within 24 hours of symptoms starting.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the brain artery after a successful mechanical clot removal can improve recovery for people with a certain type of stroke. The goal is to see if it safely helps clear any remaining tiny clots and reduces disability.
This study tests whether giving a clot-busting drug called tenecteplase directly into the brain's blood vessels can help complete the removal of a clot after a first attempt at mechanical extraction was only partially successful.
This study tests a clot-dissolving drug called tenecteplase given directly into the artery after a mechanical thrombectomy (clot removal). The goal is to see if it helps improve blood flow to the small vessels in the brain after the main clot is removed.
This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.
Hear when a new Cerebrovascular Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.